Magle Chemoswed Holding AB Ordinary Shares MAGLE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 30.20
- Day Range
- SEK 30.00–30.40
- 52-Week Range
- SEK 21.40–38.00
- Bid/Ask
- SEK 29.20 / SEK 30.00
- Market Cap
- SEK 324.00 Mil
- Volume/Avg
- 945 / 1,424
Key Statistics
- Price/Earnings (Normalized)
- 30.88
- Price/Sales
- 1.98
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 78
- Website
- https://www.maglechemoswed.com
Valuation
|
Metric
|
MAGLE
|
|---|---|
Price/Earnings (Normalized) | 30.88 |
Price/Book Value | 2.10 |
Price/Sales | 1.98 |
Price/Cash Flow | 15.34 |
Price/Earnings
MAGLE
Financial Strength
|
Metric
|
MAGLE
|
|---|---|
Quick Ratio | 0.64 |
Current Ratio | 1.06 |
Interest Coverage | 5.32 |
Quick Ratio
MAGLE
Profitability
|
Metric
|
MAGLE
|
|---|---|
Return on Assets (Normalized) | 4.02% |
Return on Equity (Normalized) | 7.09% |
Return on Invested Capital (Normalized) | 6.17% |
Return on Assets
MAGLE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qcfzsxkyv | Sprx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Btvbdzdn | Gvxbq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bjyzfhrgq | Xvvyt | $97.8 Bil | |
MRNA
| Moderna Inc | Mbhrngklh | Bwr | $41.3 Bil | |
ARGX
| argenx SE ADR | Sxhkbsgnx | Lhd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hwxtzjbjt | Qghx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dnmjxgz | Mccxcd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yvnpqbyv | Lwdjwk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ywcldlyrh | Fsjnxh | $12.5 Bil | |
INCY
| Incyte Corp | Rmqkhyfc | Mlhhjg | $11.6 Bil |